The MIDAS study aims to follow male and female LAM patients who are currently taking, have previously failed or been intolerant of, or may (at some time in the future) take mTOR inhibitors (sirolimus or everolimus) as part of their clinical care. Adult female TSC patients may also enroll, with or without lung cysts.
Lymphangioleiomyomatosis
The MIDAS study aims to follow male and female LAM patients who are currently taking, have previously failed or been intolerant of, or may (at some time in the future) take mTOR inhibitors (sirolimus or everolimus) as part of their clinical care. Adult female TSC patients may also enroll, with or without lung cysts.
Safety and Durability of Sirolimus for Treatment of LAM
-
Stanford University Medical Center, Stanford, California, United States, 94305
National Jewish Health, Denver, Colorado, United States, 80206
Mayo Clinic Jacksonville, Jacksonville, Florida, United States, 32224
Emory University School of Medicine, Atlanta, Georgia, United States, 33136
Loyola University Medical Center, Chicago, Maywood, Illinois, United States, 60153
Brigham and Women's Hospital, Boston, Massachusetts, United States, 02115
University of Michigan, Ann Arbor, Michigan, United States, 48109
Mayo Clinic Rochester, Rochester, Minnesota, United States, 55905
Washington University School of Medicine, Saint Louis, Missouri, United States, 63110
University of Rochester Medical Center, Rochester, New York, United States, 14642-8692
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
For general information about clinical research, read Learn About Studies.
18 Years to
FEMALE
No
University of Cincinnati,
Francis X McCormack, MD, STUDY_DIRECTOR, University of Cincinnati
2025-07-31